FDA Establishment Registration & NDC Labeler Code Number — FDA

FDA Drug Establishment Registration: Site-Specific Requirements.

FDA Drug Establishment Registration is strictly site-specific, meaning every individual physical manufacturing location operated by a pharmaceutical company must register independently with the FDA. This requirement applies regardless of whether the locations belong to the same corporate parent, share common ownership, or operate as subsidiaries of a larger pharmaceutical enterprise. Each manufacturing facility must complete its own separate registration submission and meet the following key requirements:

• Separate Registration Per Location: Each manufacturing location must register independently under its own physical address with FDA, ensuring accurate records of every site where drug manufacturing, processing, packaging, labeling, or testing activities occur.
• Unique DUNS Number: Every drug establishment requires its own Data Universal Numbering System (DUNS) number issued by Dun & Bradstreet, which serves as the Unique Facility Identifier (UFI) recognized by FDA. Corporate headquarters DUNS numbers cannot be used for separate manufacturing facilities.
• Individual FEI Number: FDA assigns a unique FEI (FDA Establishment Identifier) number to each registered location, serving as the permanent identifier for that specific manufacturing site in FDA databases.
• CGMP Compliance: Each registered facility must comply with Current Good Manufacturing Practice (CGMP) regulations under 21 CFR Part 211 and is subject to FDA inspections at the registered location.
• Annual Renewal: Establishment registration must be renewed annually between October 1 and December 31, with each location requiring its own renewal submission.

Upon successful registration completion, FDA assigns a unique FEI (FDA Establishment Identifier) number to each location, which serves as the permanent identifier for that specific manufacturing site in FDA databases. The FEI number remains associated with the physical location throughout the establishment’s regulatory lifecycle and is used in all subsequent FDA communications, inspection reports, and regulatory correspondence.

FDA Labeler Code: Company-Specific Identification

In contrast to the site-specific nature of establishment registration, the FDA Labeler Code operates on a company-specific basis rather than being tied to individual physical locations. The labeler code is a unique numerical identifier (5 digits in older systems, 6 digits in newer assignments) assigned by FDA to the company that labels and markets drug products in the United States, regardless of how many physical manufacturing locations that company operates.

If your pharmaceutical company holds a labeler code assigned to its corporate office and operates multiple manufacturing locations, distribution centers, or subsidiaries, the same labeler code can be used across all locations under common ownership. This allows for consistent branding and product identification across your entire corporate structure while simplifying NDC assignment for your drug portfolio. The labeler code forms the first portion of every National Drug Code (NDC) assigned to drug products marketed by your company, with the labeler code serving as the consistent identifier that links all your pharmaceutical products to your corporate entity.

The labeler code is assigned to the labeler—typically the company that owns the brand, holds the New Drug Application (NDA) or Abbreviated New Drug Application (ANDA), or markets the finished drug product to consumers and healthcare providers. Under FDA regulations, every drug establishment that manufactures, repacks, relabels, or salvages drug products must obtain its own labeler code and submit its own drug listing through SPL submissions. This includes human drug contract manufacturers who produce drugs for other companies—they must maintain their own labeler code and file drug listings for the products they manufacture, even when the finished products are marketed under the brand owner’s name and use the brand owner’s NDC on the consumer label. Contract manufacturers must also complete establishment registration for each of their manufacturing facilities, ensuring full FDA compliance across all aspects of pharmaceutical production.

Practical Examples: Establishment Registration vs. Labeler Code

To illustrate these distinctions clearly, consider a hypothetical pharmaceutical company “ABC Pharma” that operates three manufacturing facilities in different US states and one facility in India. Under FDA requirements, ABC Pharma must complete four separate establishment registrations—one for each of the four physical locations—each with its own DUNS number and resulting in four unique FEI numbers assigned by FDA. However, since all four facilities are owned by the same corporate entity, ABC Pharma needs only one labeler code that can be used for all drug products manufactured at any of these four locations and sold under the ABC Pharma brand name.

Conversely, if ABC Pharma establishes a separate legal entity (such as a subsidiary corporation or LLC) or acquires another pharmaceutical company that continues to operate as a separate legal entity, that separate entity will have its own labeler code—not because of branding, but because labeler codes are assigned to legal entities, not to corporate parents. Each separate legal entity that manufactures, labels, or distributes drug products must obtain its own labeler code, regardless of common corporate ownership The decision to maintain separate labeler codes for different brands under common ownership often depends on business considerations including brand identity, regulatory strategy, and product portfolio management.

Why These Distinctions Matter for FDA Compliance

Understanding the difference between establishment registration and labeler code requirements directly impacts your pharmaceutical company’s ability to legally manufacture and market drug products in the United States. Improper handling of either requirement can result in significant business consequences including delayed product launches when NDC assignments cannot be completed, registration rejections that prevent legal manufacturing operations, FDA Warning Letters citing compliance failures, import detention for foreign manufacturers without proper registration, and complications during routine FDA inspections or regulatory audits.

Liberty Management Group provides comprehensive FDA drug registration services for both domestic and foreign pharmaceutical manufacturers, handling both establishment registration (for each manufacturing location) and labeler code requests (for the company entity) through properly formatted SPL submissions. Our regulatory specialists ensure that each submission contains the correct data elements specific to its purpose, references the appropriate SPL templates, validates against FDA’s XML schema requirements, and processes through the Electronic Submissions Gateway without errors that could delay your regulatory approvals or product launches.